• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    6/14/24 4:31:12 PM ET
    $ANTX
    $BCLI
    $BFRG
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ANTX alert in real time by email

    Gainers

    • Kineta (NASDAQ:KA) shares moved upwards by 28.5% to $0.67 during Friday's after-market session. The company's market cap stands at $8.1 million.
    • iSpecimen (NASDAQ:ISPC) stock moved upwards by 13.99% to $0.57. The market value of their outstanding shares is at $5.6 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) shares moved upwards by 11.0% to $0.12. The market value of their outstanding shares is at $1.9 million.
    • Brainstorm Cell (NASDAQ:BCLI) shares increased by 9.08% to $0.51. The market value of their outstanding shares is at $35.9 million.
    • Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 7.53% to $2.71. The company's market cap stands at $21.2 million.
    • Can Fite Biofarma (AMEX:CANF) stock increased by 7.46% to $3.6. The company's market cap stands at $17.9 million.

    Losers

    • Nexalin Technology (NASDAQ:NXL) stock decreased by 12.4% to $0.78 during Friday's after-market session. The market value of their outstanding shares is at $5.8 million.
    • Scinai Immunotherapeutics (NASDAQ:SCNI) shares fell 11.47% to $3.09. The market value of their outstanding shares is at $1.7 million.
    • Ontrak (NASDAQ:OTRK) stock declined by 7.45% to $0.23. The company's market cap stands at $11.0 million.
    • AN2 Therapeutics (NASDAQ:ANTX) stock declined by 7.38% to $2.01. The company's market cap stands at $59.9 million.
    • CERo Therapeutics Hldgs (NASDAQ:CERO) shares decreased by 6.03% to $0.36. The company's market cap stands at $5.3 million.
    • Renovaro (NASDAQ:RENB) stock decreased by 5.49% to $1.55. The company's market cap stands at $228.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANTX
    $BCLI
    $BFRG
    $CANF

    CompanyDatePrice TargetRatingAnalyst
    CERo Therapeutics Holdings Inc.
    $CERO
    6/23/2025$30.00Hold → Buy
    D. Boral Capital
    AN2 Therapeutics Inc.
    $ANTX
    8/9/2024In-line → Underperform
    Evercore ISI
    AN2 Therapeutics Inc.
    $ANTX
    8/9/2024$5.00 → $1.00Outperform → Market Perform
    Leerink Partners
    AN2 Therapeutics Inc.
    $ANTX
    7/3/2024$5.00Market Perform → Outperform
    Leerink Partners
    AN2 Therapeutics Inc.
    $ANTX
    4/2/2024$6.00Mkt Perform → Mkt Outperform
    JMP Securities
    AN2 Therapeutics Inc.
    $ANTX
    2/13/2024$23.00 → $7.00Outperform → Market Perform
    Leerink Partners
    AN2 Therapeutics Inc.
    $ANTX
    2/12/2024$25.00 → $7.00Outperform → In-line
    Evercore ISI
    AN2 Therapeutics Inc.
    $ANTX
    2/12/2024Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ANTX
    $BCLI
    $BFRG
    $CANF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:08:31 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:06:28 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by Scinai Immunotherapeutics Ltd.

    3 - Scinai Immunotherapeutics Ltd. (0001611747) (Issuer)

    3/18/26 10:05:12 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $BCLI
    $BFRG
    $CANF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Easom Eric bought $10,665 worth of shares (10,000 units at $1.07), increasing direct ownership by 4% to 256,380 units (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    6/3/25 4:46:15 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fitzpatrick Margaret M bought $10,133 worth of shares (8,610 units at $1.18) (SEC Form 4)

    4 - AN2 Therapeutics, Inc. (0001880438) (Issuer)

    5/29/25 4:17:48 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

    4 - Nexalin Technology, Inc. (0001527352) (Issuer)

    3/13/25 4:52:26 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ANTX
    $BCLI
    $BFRG
    $CANF
    SEC Filings

    View All

    SEC Form 8-K filed by AN2 Therapeutics Inc.

    8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)

    3/20/26 4:37:10 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Bullfrog AI Holdings Inc.

    10-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    3/19/26 4:45:34 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.

    6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

    3/19/26 10:08:08 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $BCLI
    $BFRG
    $CANF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CERo Therapeutics upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded CERo Therapeutics from Hold to Buy and set a new price target of $30.00

    6/23/25 8:00:37 AM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AN2 Therapeutics downgraded by Evercore ISI

    Evercore ISI downgraded AN2 Therapeutics from In-line to Underperform

    8/9/24 8:39:40 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AN2 Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AN2 Therapeutics from Outperform to Market Perform and set a new price target of $1.00 from $5.00 previously

    8/9/24 7:16:36 AM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    $BCLI
    $BFRG
    $CANF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026

    JERUSALEM, March 19, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company advancing a pipeline of innovative inflammation and immunology therapeutics, and the owner of Scinai Biopharma Services Ltd., a rapidly expanding contract development and manufacturing organization (CDMO) serving biotechnology and pharmaceutical companies, today announced its participation in BIO-Europe Spring® 2026, taking place March 23–25 in Lisbon, Portugal. This will be Scinai's first major international conference following its recent acquisition of Recipharm Israel and strategic collaboration with Recipharm, marking a significant expansion of its development and manufact

    3/19/26 7:50:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

    Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as early as 4Q26 and throughout 2027 Advancing Phase 2 investigator-initiated trial of epetraborole in M. abscessus complex lung disease; Enrollment expected to begin in 1Q26 with topline results anticipated in late 2027 Chagas disease program progresses as Phase 1 first-in-human trial of oral AN2-502998 nears completion with initial clinical data expected in 1Q26; Initiation of Phase 2 proof-of-concept study in patients with chronic Chagas disease planned for 2026 pending results On track to advance two boron-based oncology compounds into development in 2026 March 20

    3/17/26 4:00:00 PM ET
    $ANTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

    Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE:CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that the Israeli Patent Office has allowed its patent application No. 284463, titled "An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect." The allowed patent covers the use of A3 adenosine receptor (A3AR) agonists, including the Company's lead drug candidate Namodenoson, for inducing fat loss and tr

    3/17/26 7:47:08 AM ET
    $CANF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANTX
    $BCLI
    $BFRG
    $CANF
    Leadership Updates

    Live Leadership Updates

    View All

    CERo Therapeutics Provides Shareholder Update

    Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead investor, underscore the Company's operational momentum SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, provides an update through the letter to stockholders and stakeholders from CEO Chris Ehrlich: To our stockholders and stakeholders: Following our recent Form 8-K filing confirming receipt of convertible deb

    3/11/26 8:15:00 AM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ANTX
    $BCLI
    $BFRG
    $CANF
    Financials

    Live finance-specific insights

    View All

    CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

    Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces a key clinical update from the Company's ongoing CertainT-1 trial focused on patients with acute myeloid leukemia (AML). Following completion of the dose-limiting toxicity (DLT) observation period for the first cohort, investigators observed cell expansion with no CRS, ICANS, or treatment-related adverse events reported to date. Expansion w

    1/7/26 9:09:00 AM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    NEW YORK, Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are making steady progress toward stabilizing our financial situation and initiating our Phase 3b study of NurOwn, designed to generate confirmatory data to support a potential BLA submission," said Chaim Lebovits, President and CEO. "We have been working closely with our network of clinical sites and with our selected manufacturing partners to ensure operational readiness. We also continue to engage with

    11/14/25 4:30:00 PM ET
    $BCLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet

    JERUSALEM, Sept. 2, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its financial results for the six months ended June 30, 2025. Six-Month 2025 Financial Summary  Revenues for the six months ended June 30, 2025, totaled $773 thousand, compared to $284 thousand for the six months ended June 30, 2024. The increase reflects the continued growth of the Company's CDMO business, which gener

    9/2/25 7:30:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANTX
    $BCLI
    $BFRG
    $CANF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

    SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    12/13/24 7:18:17 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by CERo Therapeutics Holdings Inc.

    SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    11/20/24 4:06:55 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by CERo Therapeutics Holdings Inc.

    SC 13G - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    11/20/24 4:01:41 PM ET
    $CERO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care